申请人:Pfizer Inc.
公开号:US04273782A1
公开(公告)日:1981-06-16
Novel 3-(1-Imidazolylalkyl)indoles and the pharmaceutically acceptable acid addition salts thereof are disclosed. The novel compounds are useful in selectively inhibiting the action of the thromboxane synthetase enzyme without significantly inhibiting the action of the prostacycline synthetase or cyclooxygenase enzymes and are thus of value as therapeutic agents for the treatment of ischaemic heart disease, stroke, transient ischaemic attack, thrombosis, migraine and the vascular complications of diabetes.
本文披露了新型3-(1-咪唑基烷基)吲哚化合物及其药用酸盐。这些新型化合物可用于选择性抑制血栓素合酶酶的作用,而不显著抑制前列环素合酶或环氧合酶的作用,因此对于治疗缺血性心脏病、中风、短暂性缺血性发作、血栓形成、偏头痛和糖尿病的血管并发症具有治疗价值。